Sartorius Group
Conference Call to Discuss Preliminary First-Half Results for 2011

Joachim Kreuzburg, CEO
Goettingen, July 25, 2011
Disclaimer

This presentation contains statements concerning the Sartorius and Sartorius Stedim Biotech Groups' future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.
## Sartorius Group's Performance in H1 2011

<table>
<thead>
<tr>
<th></th>
<th>H1 2011</th>
<th>H1 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Order Intake</td>
<td>Growth</td>
<td>382.3</td>
</tr>
<tr>
<td>Sales Revenue</td>
<td>Growth</td>
<td>353.7</td>
</tr>
<tr>
<td>Underlying(^1) EBITA</td>
<td>Margin</td>
<td>51.1</td>
</tr>
<tr>
<td>Underlying(^1)(^2) EPS in €</td>
<td></td>
<td>1.41</td>
</tr>
<tr>
<td>Operating Cash Flow</td>
<td></td>
<td>14.3</td>
</tr>
</tbody>
</table>

\(^1\) Excluding extraordinary effects  
\(^2\) Excluding non-cash amortization  

In millions of € unless otherwise specified.
Considerable Increase in Order Intake

**Biotechnology**
- Strong double-digit growth with single-use products, especially filters and bags

**Mechatronics**
- Healthy increases in both laboratory and industrial weighing businesses

---

**Currency-adjusted Growth:**
- Group: +14.6%
- Biotechnology: +17.4%
- Mechatronics: +9.2%

**Order Intake in millions of €**

- Biotechnology:
  - H1 2010: 221.4
  - H1 2011: 257.2
  - Increase: +16.2%

- Mechatronics:
  - H1 2010: 115.1
  - H1 2011: 125.1
  - Increase: +8.7%

- Group:
  - H1 2010: 336.4
  - H1 2011: 382.3
  - Increase: +13.6%
Strong Sales Revenue Growth

Sales Revenue
in millions of €

Currency-adjusted Growth:
- Group +13.1%
- Biotechnology +10.8%
- Mechatronics +17.6%

Biotechnology
- Double-digit growth with single-use products

Mechatronics
- Strong growth in laboratory business as well as in industrial weighing business
- Sales growth positively impacted by comparably low revenue base of the previous year
Sales Revenue by Region – Biotechnology

- Single-use filtration products grew dynamically across all regions
- Healthy growth of European business
- Moderate sales growth in North America, mainly due to some fluctuations in equipment business
- Strong double-digit sales growth in Asia | Pacific driven by single-use products as well as sales from relatively large equipment orders

1) According to customers' location
Sales Revenue by Region – Mechatronics

- Asia | Pacific also the fastest-growing business region for the Mechatronics Division
- Laboratory business with double-digit sales growth in all regions
- Industrial weighing business especially strong in Europe and Asia | Pacific

1) According to customers' location
Underlying\(^1\) EBITA for the Sartorius Group Increased Significantly

**Group**
- Underlying\(^1\) EBITA margin: 14.4%  
(prev. year: 11.5%)

**Biotechnology**
- Underlying\(^1\) EBITA margin: 16.8%  
(prev. year: 15.0%)
- Main profit driver: economies of scale

**Mechatronics**
- Underlying\(^1\) EBITA margin: 10.0%  
(prev. year: 4.5%)
- Significant increase in profitability due to dynamic growth and optimized cost structure

---

\(^1\) Excluding extraordinary effects
Strong Gain Also in Underlying\(^1\) EBITDA

**EBITDA**  
Underlying\(^1\), in millions of €

<table>
<thead>
<tr>
<th>Group</th>
<th>H1 2010</th>
<th>H1 2011</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
<td>48.5</td>
<td>63.5</td>
<td>31.0%</td>
</tr>
<tr>
<td>Biotechnology</td>
<td>39.4</td>
<td>46.9</td>
<td>19.0%</td>
</tr>
<tr>
<td>Mechatronics</td>
<td>9.1</td>
<td>16.6</td>
<td>82.9%</td>
</tr>
</tbody>
</table>

\(^1\) Excluding extraordinary effects

**Group**
- **Underlying\(^1\)** EBITDA margin: 18.0%  
  (prev. year: 15.4%)

**Biotechnology**
- **Underlying\(^1\)** EBITDA margin: 20.4%  
  (prev. year: 18.8%)

**Mechatronics**
- **Underlying\(^1\)** EBITDA margin: 13.4%  
  (prev. year: 8.6%)
Strong Increase in Underlying\(^1\) Earnings per Share

Earnings per Share
Underlying\(^1\), in €

<table>
<thead>
<tr>
<th></th>
<th>H1 2010</th>
<th>H1 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.93</td>
<td>1.41</td>
<td></td>
</tr>
</tbody>
</table>

\(+50.6\)%

Net Profit
Underlying\(^1\), in millions of €

<table>
<thead>
<tr>
<th></th>
<th>H1 2010</th>
<th>H1 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.9</td>
<td>24.0</td>
<td></td>
</tr>
</tbody>
</table>

\(+50.6\)%

Unadjusted consolidated net profit after minority interest: €18.7 mn (€12.1 mn)

\(^1\) Excluding extraordinary effects and non-cash amortization
**All Key Financial Indicators at a Very Comfortable Level**

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2011</th>
<th>December 31, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity Ratio in %</td>
<td>39.9</td>
<td>40.5</td>
</tr>
<tr>
<td>Net Debt in € mn</td>
<td>217.1</td>
<td>196.9</td>
</tr>
<tr>
<td>Gearing</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Net Debt to Underlying(^1) EBITDA</td>
<td>1.7</td>
<td>1.8</td>
</tr>
<tr>
<td>Interest Coverage(^1)</td>
<td>14.7</td>
<td>15.4</td>
</tr>
</tbody>
</table>

\(^1\) Excluding extraordinary effects
FY 2011 Guidance Raised

- Management further forecasts a significantly positive operating cash flow
- Capex ratio expected to be around 7% due to infrastructure projects in SSB

<table>
<thead>
<tr>
<th></th>
<th>FY 2010 Sales Revenue</th>
<th>Former Guidance Sales Growth(^1)</th>
<th>New Guidance Sales Growth(^1)</th>
<th>FY 2010 EBITA Margin(^2)</th>
<th>Former Guidance EBITA Margin(^1)/(^2)</th>
<th>New Guidance EBITA Margin(^1)/(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sartorius Group</td>
<td>€659.3 mn</td>
<td>6% – 8%</td>
<td>8% – 10%</td>
<td>13.0%</td>
<td>Around 14%</td>
<td>14.5% – 15.5%</td>
</tr>
<tr>
<td>Biotechnology</td>
<td>€432.6 mn</td>
<td>6% – 8%</td>
<td>8% – 10%</td>
<td>16.2%</td>
<td>Around 17%</td>
<td>17% – 18%</td>
</tr>
<tr>
<td>Mechatronics</td>
<td>€226.7 mn</td>
<td>6% – 8%</td>
<td>8% – 10%</td>
<td>6.8%</td>
<td>Around 8%</td>
<td>10% – 11%</td>
</tr>
</tbody>
</table>

\(^1\) In constant currencies
\(^2\) Excluding extraordinary effects
Sartorius Stedim Biotech Group
Conference Call to Discuss Preliminary First-Half Results for 2011

Joachim Kreuzburg, CEO
Goettingen, July 25, 2011
SSB Group's Performance in H1 2011

<table>
<thead>
<tr>
<th></th>
<th>H1 2011</th>
<th>H1 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Order Intake</td>
<td>Growth</td>
<td>257.4</td>
</tr>
<tr>
<td>Sales Revenue</td>
<td>Growth</td>
<td>229.6</td>
</tr>
<tr>
<td>Underlying(^1) EBITA</td>
<td>Margin</td>
<td>38.6</td>
</tr>
<tr>
<td>Underlying(^1)(^2) EPS in €</td>
<td></td>
<td>1.63</td>
</tr>
<tr>
<td>Operating Cash Flow</td>
<td>13.8</td>
<td>24.9</td>
</tr>
</tbody>
</table>
Considerable Increase in Order Intake and Sales Revenue

- Double-digit growth in order intake and sales with single-use products

**Order Intake**
in millions of €

- 2010: 221.6
- 2011: 257.4

**Sales Revenue**
in millions of €

- Currency-adjusted:
  - Order Intake: +17.4%
  - Sales: +10.8%

- 2010: 209.3
- 2011: 229.6
### Highest Revenue Gains in Asia | Pacific

<table>
<thead>
<tr>
<th>Region</th>
<th>Sales¹ in millions of €</th>
<th>Growth %</th>
</tr>
</thead>
<tbody>
<tr>
<td>North America</td>
<td>54.0</td>
<td>+2.7 %</td>
</tr>
<tr>
<td>Europe</td>
<td>123.4</td>
<td>+8.8 %</td>
</tr>
<tr>
<td>Asia</td>
<td>Pacific</td>
<td>43.6</td>
</tr>
<tr>
<td>Other Markets</td>
<td>8.5</td>
<td>+2.2 %</td>
</tr>
</tbody>
</table>

- Single-use filtration products grew dynamically across all regions
- Healthy growth of European business
- Moderate sales growth in North America, mainly due to some fluctuations in equipment business
- Strong double-digit sales growth in Asia | Pacific driven by single-use products as well as sales from relatively large equipment orders

¹) According to customers' location
Overproportionate Profitability Growth

- Underlying\(^1\) EBITA margin: 16.8\% (prev. year: 15.0\%)
- Underlying\(^1\) EBITDA margin: 20.4\% (prev. year: 18.8\%)
- Main profit driver: economies of scale

\(^1\) Excluding extraordinary effects
Strong Increase in Underlying\(^1\) Earnings per Share

<table>
<thead>
<tr>
<th>Earnings per Share Underlying(^1), in €</th>
<th>Net Profit Underlying(^1), in millions of €</th>
</tr>
</thead>
<tbody>
<tr>
<td>+38.4%</td>
<td>+28.3%</td>
</tr>
<tr>
<td>1.63</td>
<td>25.0</td>
</tr>
<tr>
<td>1.18</td>
<td>19.5</td>
</tr>
</tbody>
</table>

\(^1\) Excluding extraordinary effects and non-cash amortization

- Unadjusted consolidated net profit: €20.3 mn (prev. year: €16.7 mn)
All Key Financial Indicators at a Very Comfortable Level

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2011</th>
<th>December 31, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity Ratio in %</td>
<td>53.9</td>
<td>55.6</td>
</tr>
<tr>
<td>Net Debt in € mn</td>
<td>114.4</td>
<td>102.8</td>
</tr>
<tr>
<td>Gearing</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Net Debt to Underlying(1)\ EBITDA</td>
<td>1.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Interest Coverage(1)\</td>
<td>23.6</td>
<td>25.8</td>
</tr>
</tbody>
</table>

\(1\) Excluding extraordinary effects
FY 2011 Guidance Raised

<table>
<thead>
<tr>
<th>FY 2010 Sales Revenue</th>
<th>Former Guidance Sales Growth(^1)</th>
<th>New Guidance Sales Growth(^1)</th>
<th>FY 2010 EBITA-Margin(^2)</th>
<th>Former Guidance EBITA Margin(^1,2)</th>
<th>New Guidance EBITA Margin(^1,2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>€432.9 mn</td>
<td>6% – 8%</td>
<td>8% – 10%</td>
<td>16.2%</td>
<td>Around 17%</td>
<td>17% – 18%</td>
</tr>
</tbody>
</table>

- Management further forecasts a significantly positive operating cash flow
- Capex ratio expected to be around 8% due to infrastructure projects

\(^1\) In constant currencies
\(^2\) Excluding extraordinary effects
Thank you very much for your attention.

Joachim Kreuzburg, CEO
Goettingen, July 25, 2011